osinophilic gastritis (EG) and eosinophilic gastroenteritis (EGE) are rare diseases characterized by marked eosinophilic infiltration of the gastrointestinal (GI) tract, and symptoms that typically reflect the location(s) of GI involvement.
1,2 Knowledge of these conditions is limited, and treatments, which largely are based on case series, most frequently involve corticosteroids. Because long-term steroid treatment is fraught with complications, novel treatment options are needed.
Vedolizumab is a humanized monoclonal antibody to the a4b7 integrin that blocks leukocyte migration into GI mucosa. 3 Vedolizumab is approved for the treatment of moderate to severe inflammatory bowel disease (IBD), and provides benefit via inhibition of gastrointestinalhoming of T lymphocytes. 4 However, there is evidence that increased levels of eosinophils can be associated with IBD and may play a role in IBD pathogenesis, that the a4b7 integrin may play an important role in eosinophil localization in IBD, and that blocking a4b7 may inhibit eosinophil recruitment to intestinal mucosa. 5, 6 Based on this eosinophil effect, there is a strong rationale that vedolizumab may benefit patients with EG/EGE, but there have been no clinical trials in these conditions. Therefore, this study aimed to assess whether vedolizumab therapy is associated with improved clinical symptoms, endoscopic features, and histologic findings in patients with EG/EGE who failed to respond to prior therapies.
Methods
We conducted a retrospective cohort study of patients with confirmed EG or EGE treated with off-label use of vedolizumab at University of North Carolina Hospitals from 2015 through 2017. Cases were defined by a peak eosinophil count of 30 or more eosinophils per high-power field on either gastric or duodenal biopsy, which is consistent with prior reports given there are no diagnostic guidelines for these conditions. 1, 7 Data regarding symptoms, endoscopic features, tissue eosinophil counts, peripheral blood absolute eosinophil counts, and treatments before and after vedolizumab were extracted from the electronic medical record. Outcomes included clinical response (global assessment by the patient), ability to wean systemic steroids and other medications, improvement in endoscopic findings (global assessment by the endoscopist), and a decrease in tissue eosinophil counts. This study was approved by the University of North Carolina Institutional Review Board (15-2882).
Results
We identified 5 adults with EG/EGE who were treated with vedolizumab (Table 1) . Ages ranged from 23 to 54 years, 40% were female, and all patients were white. Three patients had gastric involvement, all had smallbowel involvement, 1 had colonic involvement, and 3 had overlapping esophageal involvement; 2 had proteinlosing enteropathy. At diagnosis, counts ranged from 80 to 400 eosinophils per high-power field in the most highly involved location. Before vedolizumab, all patients had been treated with systemic steroids and topical/enteralrelease steroids, 4 with elimination diets, 4 with cromolyn, all with immunomodulators, 1 with infliximab, and 1 with omalizumab. Patients had a disease course of 6.5 to 17.2 years before treatment with vedolizumab, and received vedolizumab for 0.2 to 1.3 years (median, 0.6 y).
After vedolizumab, patients 4 and 5 were able to wean and/or discontinue corticosteroids, reported symptom improvement, and had normal gastric and small intestinal biopsies (Table 1) . Patient 1 reported symptom improvement, but declined a repeat endoscopic evaluation. Patients 2 and 3 reported no change in symptoms and eosinophil counts did not consistently improve. No patients had documented improvement in endoscopic findings. Esophageal eosinophils increased in patient 3 and peripheral blood eosinophils increased in patient 4. The median time to initial histologic followup evaluation was 2.2 months.
Discussion
Corticosteroids remain the mainstay of treatment for EG/EGE. However, patients often require long-term steroid treatment owing to a relapsing course that necessitates maintenance therapy. Because of undesired adverse effects associated with prolonged systemic steroid use, alternatives have been proposed including topical/enteral-release steroids, elimination diets, leukotriene inhibitors, mast-cell stabilizers, antihistamines, immunomodulators, and immunosuppressants. However, the efficacy of such therapies has been controversial, side effects of immunomodulators and immunosuppressants are a concern, and data are limited to case reports or small case series. 1, 7, 8 In our severely ill group of treatment-refractory or steroid-dependent patients with EG/EGE, 2 of 5 (40%) had overall clinical and histologic improvement with vedolizumab, and were able to decrease or wean systemic steroids. An additional patient had clinical improvement but did not undergo repeat endoscopic evaluation. Our study was limited by a small sample size with no uniform follow-up evaluation. However, these results suggest that more formal assessment of vedolizumab is warranted in EG/EGE, although perhaps in a less-refractory population in whom its effect as a steroid-sparing agent could be studied. In addition, a mechanistic understanding of the effect of vedolizumab on GI infiltration of eosinophils is needed because we observed some increase in esophageal and peripheral blood eosinophilia.
